Preview

Cardiovascular Therapy and Prevention

Advanced search

Prevalence and specific features of metabolic syndrome in urban adult population

Abstract

Aim. To study the prevalence and specific clinical features of metabolic syndrome (MS) in a random sample of urban adult population. Material and methods. In total, 1800 participants were randomly selected: 749 men and 1051 women, aged 30-69 years. The study protocol was completed by 1570 subjects: 620 men and 950 women (response rate 87,2%). All participants underwent standard questionnaire survey, anthropometry, and the measurement of blood pressure (BP), blood lipids, and blood glucose (fasting glycemia and glycemia at 2 hours after oral glucose tolerance test). Results. According to the NCEP ATP III criteria, MS was registered in 314 participants (20,6%), and according to the IDF criteria – in 447 (28,5%; p<0,0001). On average, MS was twice as prevalent in women as in men. In both genders, advanced age was associated with increasing MS prevalence. The majority of the participants had three MS components (61,5%). Four MS components were registered in 28,7%, and all the components were observed in 9,8%. The most prevalent MS component was low level of high-density lipoprotein cholesterol (68,8%), followed by hypertriglyceridemia (65,3%), abdominal obesity by ATP III criteria (65%), arterial hypertension, AH (65%), and hyperglycemia (45,2%). Each third respondent with MS demonstrated clinical manifestations of atherosclerosis, such as coronary heart disease, myocardial infarction in anamnesis, peripheral or cerebrovascular atherosclerosis. Conclusion. Among this working-age population, MS prevalence was 20%. The most common MS components included dyslipidemia, AH, and abdominal obesity. Each third MS patient had various manifestations of cardiovascular pathology.

About the Authors

Z. N. Tokareva
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation


M. N. Mamedov
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation


A. D. Deev
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation


A. A. Evdokimova
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation


R. G. Oganov
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation


References

1. Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология 2004; 44(9): 4-8.

2. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37; 1595-607.

3. Isomaa B., Almgren P., Tuomi T., Forsen B. Cardiovascular morbidity and mortality associated with the metabolic syndrome (Botnia Study). Diabetes Care 2001; 24(4): 683-9.

4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program. JAMA 2001; 285: 2486-97.

5. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9.

6. Balkau B., Charles M.A., Drivsholm T., et al. Frequence of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28(5): 364-76.

7. L'italien G., Kan H. The metabolic syndrome as an independent predictor of diabetes, cardiovascular disease and all cause mortality: a meta-analysis of recent studies. J Diabetes 2009; l(Suppll):A83.

8. Jones E.D., Ivanov L.L., Wallace D.C., VonCannon L. Examining the metabolic syndrome in Russia. Int J Nurs Pract 2006; 12(5): 260-6.

9. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetes Med 2007; 24: 451-63.

10. Алмазов В., Благосклонная Я., Шляхто Е., Красильникова Е. Метаболический сердечно-сосудистый синдром. Санкт Петербург 1999; 8-12, 68, 157-61.

11. Ford E.S., Li С., Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31(9): 1898-904.

12. McNeil A., Rosamond W., Girman C., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 285-390.

13. Мамедов М.Н. Метаболический синдром -больше, чем сочетание факторов риска: принципы диагностики и лечения. Издание "Верваг фарма". Москва 2006; 7-42.

14. Alberti K.G., Zimmet P., Shaw I. The metabolic syndrome -a new worldwide definition. Lancet 2005; 366: 1059-62.

15. Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic med 2003; 20(9): 693-702.

16. Saely C.H., Vonbank A., Rein P. Adult treatment Panel III metabolic syndrome criteria more strongly than international diabetes federation criteria predict the incidence of type 2 diabetes in angiographied coronary patients. J Diabetes 2009; l(Suppl 1):A84.


Review

For citations:


Tokareva Z.N., Mamedov M.N., Deev A.D., Evdokimova A.A., Oganov R.G. Prevalence and specific features of metabolic syndrome in urban adult population. Cardiovascular Therapy and Prevention. 2010;9(1):10-14. (In Russ.)

Views: 597


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)